DECR1 and neoplasm: 2,4-dienoyl coenzyme A reductase (DECR1), a beta-oxidation coenzyme, is a clinically relevant biomarker for CRPC, and DECR1 deficiency impairs lipid metabolism and reduces CRPC tumor growth (29).